SMTI Share Price Performance
US$19.14
-18.18 (-48.71%)
53.3% undervalued intrinsic discount
US$41.00
Fair Value
Price US$19.14
AnalystConsensusTarget US$41.00
Fair ValueUS$41.00
Share Pricen/a
Sanara MedTech Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
SMTI Community Narratives
AN
Fair Value US$41 53.3% undervalued intrinsic discount
Expanding Hospital Networks And Digital Health Will Fuel Growth
2users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Expanding Hospital Networks And Digital Health Will Fuel Growth
Key Takeaways Expanding clinical adoption and distribution, plus proprietary product focus, set up Sanara for sustained growth and stronger margins in high-demand wound and surgical care markets. Advancements in digital health and disciplined expense management are positioning the company for scalable, high-margin recurring revenues and improved overall profitability.Read more
2users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$41
53.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
13.25% p.a.
Profit Margin
32.45%
Future PE
9.76x
Share price in 2028
US$49.21
Recently Updated Narratives
AN
Expanding Hospital Networks And Digital Health Will Fuel Growth
Fair Value: US$41 53.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sanara MedTech Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.68
- 92.25%
- -5.96%
- 734.3%
About SMTI
- Founded
- 2001
- Employees
- 141
- CEO
- WebsiteView website
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
